|Mr. Matthew R. Kane||Co-Founder, CEO, Pres & Director||518.52k||N/A||1977|
|Mr. Abid Ansari||Chief Financial Officer||347.55k||N/A||1978|
|Dr. David S. Thomson Ph.D.||Chief Operating Officer||490.25k||N/A||1961|
|Dr. Jefferson J. Smith Ph.D.||Co-Founder & CTO||N/A||N/A||N/A|
|Dr. Derek Jantz Ph.D.||Co-founder, Chief Scientific Officer & Director||N/A||N/A||1976|
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.